4
Changes in Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-19-010837
Executive VP, Global R&D sold 1,841 shares at $17.67 ($32,529)
- Executive VP, Global R&D acquired 5,353 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Fridriksdottir Hafrun · Executive VP, Global R&D
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2019-02-14 | Exercise or conversion : show line 1 in the form | +5,353 | 17,178.51 | D | ||
| 2019-02-14 | Sale : show line 2 in the form | −1,841 | $17.67 | $32,529 | 15,337.51 | D |
| Open-market sales · 1,841 sh · avg $17.67 · $32,529 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2019-02-14 | Exercise or conversion : show line 3 in the form Restricted Share Units | −5,353 | 10,708 | D |
Loading xslF345X03/doc4.xml…